Project Scope |
Scope is limited to digital biomarkers usage in Clinical Trials. |
| Problem Statement |
|---|
Digital biomarkers are defined as objective, quantifiable physiological and behavioural data that are collected and measured by means of digital devices such as portables, wearables, implantables, or digestibles. As an emerging technology, Digital Biomarkers ability in addressing medical challenges is enormous. Project “DB360”, to focus on all areas surrounding Digital Biomarkers and its usage in clinical trials. You can find further information here. |
| Problem Impact |
|---|
This project identifies current state of digital biomarkers in clinical sector and its future impact. It will cover the topics: Classification of existing digital biomarkers, Clinical Therapeutic areas where digital biomarkers usage is progressing, limitations, etc., Stakeholders impacted are Pharma, CROs, tech companies, regulators and SDOs. “DB360” will be built on the paper DH08 submitted in PHUSE US Connect 2020 with final outcome of White Paper and presentations at PHUSE conferences in 2022. |
| Project Leads | |
|---|---|
| Vijay Pasapula (Cerus) | VPasapula@cerus.com |
| Unnat Patel (AnalysisMate) | unnat.patel@analysismate.com |
| Alex Pearce (PHUSE Project Assistant) |
CURRENT STATUS Q2 2023 |
|---|
In the process of expanding scope to "Digital Health Technologies". |
| Objectives & Deliverables | Timelines |
|---|---|
Proposing to broaden scope to "Digital Health Technologies" | Q2 2023 |
Recruit additional members through call for volunteers | Q2 2023 |
Present poster at PHUSE/FDA CSS 2023 | Q3 2023 |